Synaptogenix Stock Price, News & Analysis

Synaptogenix (Nasdaq: SNPX), a biopharmaceutical company focused on neurodegenerative diseases, announced a new patent awarded by the U.S. Patent Office for methods to induce synaptogenesis using growth factor activating compounds. This patent is particularly relevant for the lead drug, Bryostatin-1, which targets synaptic growth factors and aims to prevent neuronal death. Bryostatin has shown potential in treating Alzheimer's, Parkinson's, multiple sclerosis, and Fragile X syndrome. The company has a significant safety database from prior cancer studies involving over 1,500 participants.

Synaptogenix, Inc. (SNPX) announced that Dr. Daniel Alkon, President and CSO, will appear on TD Ameritrade Network's "The Watch List" on June 25, 2021, at 1:20 PM ET. He will discuss Synaptogenix's lead drug Bryostatin-1, focusing on its regenerative mechanism for treating Alzheimer's disease and its implications for future therapies following Biogen's recent drug approval. Synaptogenix is developing therapies for neurodegenerative diseases and has received Orphan Drug Designation for Bryostatin-1 aimed at Fragile X syndrome, highlighting the drug's clinical significance.

On June 14, 2021, Synaptogenix (Nasdaq: SNPX) announced a private placement financing to raise approximately $12.5 million. This funding will primarily support the ongoing Phase 2b trial of Bryostatin-1 for Alzheimer's disease, sponsored by the NIH, and further R&D for new indications. Each Unit consists of one share of common stock and one warrant priced at $7.547. The transaction, set to close on June 16, 2021, subject to customary conditions, reflects strong support from existing institutional shareholders.

Synaptogenix, Inc. (Nasdaq: SNPX) has provided an update on its Phase 2b clinical trial of Bryostatin-1 for Alzheimer's disease, with 58 out of 100 targeted patients dosed. The independent Data Safety Monitoring Board reported no significant safety concerns after dosing 40 advanced AD patients. CEO Alan Tuchman highlighted the growing evidence supporting Bryostatin-1's safety, especially compared to other Alzheimer's drugs. Historical pilot trials showed a 4.8 improvement in the Severe Impairment Battery Score, maintaining safety as a primary objective.

Synaptogenix, Inc. (Nasdaq: SNPX) praised Biogen's FDA approval of Aducanumab for Alzheimer's treatment, emphasizing its commitment to innovative therapies for the disease. While acknowledging Biogen's efforts, Synaptogenix focuses on a restorative approach through its lead compound, Bryostatin-1, currently in an extended clinical trial. Bryostatin-1 is designed to regenerate brain synaptic networks and reduce amyloid levels. The company has previously conducted substantial studies on Bryostatin-1, establishing a robust safety database. The FDA has granted it Orphan Drug Designation for Fragile X syndrome.

Synaptogenix, Inc. (OTC: SNPX) has received approval to uplist to The Nasdaq Capital Market, effective June 7, 2021. This uplisting marks a significant milestone for the biopharmaceutical company, which focuses on treatments for neurodegenerative diseases. CEO Alan Tuchman and President Daniel Alkon emphasized that this transition will enhance visibility and outreach to investors. The company's lead therapeutic candidate, Bryostatin-1, has shown promise in clinical studies for conditions like Alzheimer's and Fragile X syndrome. The FDA has granted Orphan Drug Designation to Bryostatin-1 for Fragile X.

Synaptogenix, Inc. (OTC: SNPX) has approved a one-for-four reverse stock split to meet Nasdaq listing requirements, effective May 19, 2021. This decision aims to enhance the company’s visibility and liquidity in the market. Post-split, approximately 3,508,129 shares will remain outstanding. Although the company is optimistic about the uplisting, it cautions that there are no guarantees of meeting Nasdaq's criteria. The initiative is part of Synaptogenix's broader strategy to advance its lead candidate, Bryostatin-1, for treating neurodegenerative diseases.

Synaptogenix, Inc. (OTC: SNPX) announced that Dr. Daniel Alkon will present a "Spotlight Showcase" titled "Regenerative Therapeutics" on April 28, 2021, at 12:40 PM ET. The showcase highlights Synaptogenix's work on therapies for neurodegenerative diseases, particularly focusing on Bryostatin-1, which may restore cognitive function by inducing new synaptic connections. Ongoing NIH-supported trials are underway, aiming to assess Bryostatin-1's efficacy in Alzheimer's disease and other disorders. The presentation will be available on demand for registered participants and via social media after the event.

Synaptogenix, Inc. (OTC: SNPX) has provided an update on its Phase 2b clinical trial of Bryostatin-1 for moderately severe Alzheimer's disease. The trial has dosed 43 out of 100 targeted patients across 17 sites, with no safety issues reported. The trial aims for two 11-week dosing cycles and seeks to replicate a previous improvement of 4.8 Severe Impairment points. The CEO noted that enrollment is on track despite potential COVID-19 impacts, emphasizing a structured trial duration to mitigate placebo effect risks.